Considering vitiligo-like depigmentation in (melanoma) patients receiving anti-PD-1 monotherapy, vitiligo patients may benefit from induced peripheral tolerance to self-proteins by exploiting the T cell immunosuppression mediated by these molecules. The gene discussed is PDCD1; the disease is melanoma.